Director, US BD&L and Commercial Mergers & Integrations
Novartis
Summary
The Director, US BD&L will work under the leadership of the ED US BD&L and Commercial Mergers & Integrations to partner with an extended team of US cross functional experts providing strategic support across therapeutic areas, with a preference for candidates who bring relevant expertise through scientific, clinical, pipeline, commercial, or BD&L experience. This individual will help ensure strong US perspective and alignment across asset assessments, opportunity prioritization, and cross-functional input, while supporting effective partnership with the global team in Strategy and growth (BD&L) as well as the M&A group.
Job description
Key Responsibilities
- Coordinate clear and timely US input across TA pipeline leads and relevant line functions to support high-quality BD&L assessments and recommendations.
- In close collaboration with the data and insights team, integration of insights and recommendation for all sources of external data, including analysts’ reports, enterprise level competitive intelligence.
- Serve as an effective bridge between US stakeholders, Strategy & Growth, TASH, and Global teams to ensure aligned, actionable, and well-integrated US perspectives.
- Lead cross-TA coverage, with a preferred core focus and deeper expertise in Cardiovascular/Cardiology and related pipeline areas, while remaining flexible and able to integrate knowledge across other therapeutic areas, including Neuroscience, Oncology, and Immunology, as US BD&L priorities, bandwidth, and business needs evolve.
- Support merger, acquisition, and integration preparedness by contributing to coordinated US BD&L input, while demonstrating the agility, operational discipline, and people-management skills needed to pivot and support integration work during an acquisition or other priority enterprise initiatives.
Essential Requirements
- Bachelor’s Degree required; MBA, scientific, clinical, or health policy degree preferred.
- 8+ years of relevant pharmaceutical industry experience, such as commercial strategy, BD&L, pipeline strategy, insights and analytics, modeling, finance, access, or related functions.
- Strong understanding of the commercialization process, pipeline assessment, coverage and reimbursement considerations, and cross-functional decision-making.
Desirable Requirements
- Cardiovascular/Cardiology expertise preferred, ideally through scientific, clinical, pipeline, commercial, or BD&L experience.
Requirements
- Bachelor’s Degree required
- MBA, scientific, clinical, or health policy degree preferred
- 8+ years of relevant pharmaceutical industry experience
- Experience in commercial strategy, BD&L, pipeline strategy, insights and analytics, modeling, finance, access, or related functions
- Strong understanding of the commercialization process
- Pipeline assessment experience
- Coverage and reimbursement considerations knowledge
- Cross-functional decision-making skills
- Cardiovascular/Cardiology expertise preferred
Benefits
- Health benefits
- Life insurance
- Disability benefits
- 401(k) with company contribution and match
- Performance-based cash incentive
- Annual equity awards
- Vacation
- Personal days
- Holidays
Company overview
Novartis is a global pharmaceutical company headquartered in Basel, Switzerland, dedicated to reimagining medicine to improve and extend people's lives. As an innovative medicines company, Novartis focuses on developing high-value treatments that address society's greatest disease burdens through technology leadership in research and development. The company operates across five core therapeutic areas: cardiovascular, renal and metabolic diseases; immunology; neuroscience; oncology; and hematology. With a workforce of approximately 75,883 employees worldwide, Novartis reaches nearly 300 million patients across 118 countries. The company leverages advanced technology platforms including targeted protein degradation, cell therapy, gene therapy, radioligand therapy, and xRNA to develop breakthrough treatments. Novartis maintains a strong portfolio of oncology drugs and generics while continuously expanding its pipeline through strategic acquisitions and internal research. The company's commitment extends beyond drug development to ensuring global access to medical innovations through novel access approaches and patient assistance programs.